The impact of aspirin use on breast cancer subtype and clinical course

Repurposing of drugs for triple negative breast cancer: an overview

“…The articles of Shiao et al [ 19 ] and Williams et al [ 20 ] showed conflicting results on aspirin. While the first study showed a significant survival benefit in women with stage II/III by the use of aspirin, Williams et al [ 20 ] did not show this benefit in the breast cancer population examined (women with operable stage I-III TNBC).…”

“…Clinical evidence on twelve licensed drugs was found, and of these drugs, eleven out of 268 (4.1%) were included in ReDO_DB. Eleven studies out of 18 were retrospective studies [ 10 – 13 , 17 , 19 , 20 , 22 , 25 , 26 ], six were phase II and [ 14 – 16 , 18 , 21 , 23 ] one was a phase I clinical trial [ 24 ] (see Figure 1 for more details). Retrospective studies ranged from 1995 to 2016, and six out of eleven studies analysed a USA cohort of patients [ 10 , 12 , 19 , 20 , 25 , 26 ].…”

“…Eleven studies out of 18 were retrospective studies [ 10 – 13 , 17 , 19 , 20 , 22 , 25 , 26 ], six were phase II and [ 14 – 16 , 18 , 21 , 23 ] one was a phase I clinical trial [ 24 ] (see Figure 1 for more details). Retrospective studies ranged from 1995 to 2016, and six out of eleven studies analysed a USA cohort of patients [ 10 , 12 , 19 , 20 , 25 , 26 ]. Eight studies were performed using medical records [ 10 , 12 , 17 , 19 , 20 , 22 , 25 , 26 ], one was based on disease registries [ 11 ] and two reported the results of previous clinical trials [ 13 ].…”

“…Retrospective studies ranged from 1995 to 2016, and six out of eleven studies analysed a USA cohort of patients [ 10 , 12 , 19 , 20 , 25 , 26 ]. Eight studies were performed using medical records [ 10 , 12 , 17 , 19 , 20 , 22 , 25 , 26 ], one was based on disease registries [ 11 ] and two reported the results of previous clinical trials [ 13 ]. Of the 18 clinical studies collected, four analysed the efficacy of beta blockers (BB) [ 11 – 13 ], five of non-steroidal anti-inflammatory drugs (NSAIDs) [ 17 – 21 ], two of zoledronic acid [ 15 , 16 ], one of metformin [ 10 ], one of tetramolybdate [ 14 ], one of itraconazole [ 22 ], one of esomeprazole [ 23 ], one of mifepristone [ 24 ] and two of statins [ 25 , 26 ].…”

“…Five years overall survival hazard ratio was not significant between the two arms (HR: 0.652 (0.343–1.239); p = 0.192). The second retrospective study of Williams et al [ 20 ] performed in USA used electronic medical records of 147 women with primary operable stages I-III TNBC (114 never used aspirin, 19 before diagnosis, and 14 after diagnosis) to analyse overall survival and disease-free survival between 2005 and 2013. Results of this study indicated that aspirin may have an impact on the pathogenesis of TNBC but do not seem to affect breast cancer survival when used after cancer diagnosis (results were presented only for the total cohort of breast cancer patients and not for TNBC subtype).…”